Optical imaging of intrinsic signals was performed with Imager 2001 VSD+ (Optical Imaging System Inc., Germantown, NY) using imaging methods slightly modified from those described elsewhere [8], [9], [35], [91].
To evaluate the targeting of CF750-A33scFv-Fc in an orthotopic LS174T tumor transplantation mice model, the injected mice were first imaged using the optical imaging system from the abdomen without laparotomy.
Absorbance, scatter and background fluorescence were imaged using a reflectance optical imaging system.
Subsequently, the injected mice were imaged using inan IVIS optical imaging system (Caliper Life Sciences, CA, USA) at different time points.
Because these prodrugs have the same fluorescence photosensitizer, Pc, we expected that all prodrugs could be imaged using a preclinical optical imaging system (IVIS imaging system), and that FR-mediated uptake in tumors could be readily visualized.
All the mice were imaged by live small animal optical imaging system (IVIS Lumina XR, Caliper) at 1, 4, or 24 h following injection.
For biodistribution studies, the mice were imaged by the IVIS-200 optical imaging system (Xenogen Corp., Almeda, CA) at 0, 15, 30, and 60 min, and 2, 4, 6, and 24 h postinjection.
Mice were anesthetized with an intraperitoneal injection of ketamine (75 mg/kg) and medetomidine (1 mg/kg), placed in an upright position in the imaging chamber and then imaged using the VisEn FMT Optical Imaging System (PerkinElmer).
Animals were imaged in the Xenogen IVIS-50 optical imaging system at the indicated time described in the article.
The luminescence images were obtained on an IVIS Lumina optical imaging system with various band-pass filters.
EGFP signal was imaged and quantified using a bonSAI fluorescence optical imaging system immediately after injection, daily for four days, and then every 2 3 days.
